Topotecan is currently approved in the US in two second-line settings: metastatic ovarian carcinoma, and chemosensitive small-cell carcinoma which has progressed at least 60 days after response to initial therapy. Toxicities Dose-limiting toxicity is myelosuppression, especially leukopenia, though anemia...
Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH–cortisol and renin–angiotensin–aldosteroneSequential chemotherapyFOLFIRIFOLFOXEndocrine axisACTH–cortisolRenin–angiotensin–aldosteroneThe chemotherapies of FOLFOX (leucovorin+5-fluorouracil+oxaliplatin) and FOLFIRI (folinic acid...
(eg Pneumobilia) that it might be headed there or already is there. So its spread. Friday, Kathleen will start the FOLFIRI, which is asecond line chemo. Supposedly the side effects are not as bad as FOLFOX, but everyone reacts differently. As its a second line drug, it is normally ...
ChineseJournalofMedicinalGuide2014Volume16No.3(SerialNo.125)456结肠癌一旦确诊,20%～30%已属晚期,丧失手术机会,预期寿命仅为8个月,远处转移是结肠癌患者主要的死亡原因,约30%结肠癌根治术后死于肿瘤复发[1,2]。常用的一线治疗方案是FOLFOX方案和FOLFIRI方案[3]。2个方案在有效率和生存期方面无差别,因此NCCN指南...
The first thermotherapy treatment was FOLFOX6; the second thermotherapy treatment was FOLFIRI;14-day cycle, two times was one course; alternated use of the two chemotherapies, clinical efficacy were assessed after each 2 chemotherapies by rechecking, the patients received 4~6 thermotherapy treatment...
The prognostic impact of tumor sidedness also differs in that right-sided mCRCs have poor prognosis and have limited benefit from systemic chemo- and targeted therapy. The CALGB/SWOG 80405 study demonstrated that KRAS wild-type metastatic right-sided colon cancers had a shorter median OS than ...
(ECOG) performance status 0–1, and to have received prior therapy with ≤3 DNA-damaging agents or cytotoxic chemotherapies within the past 2 years. Patients were also required to have adequate haematologic function (absolute neutrophil count ≥ 1500 per mm3, platelets ≥ 100,000 per ...
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo−/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011;25(6):983–90. CAS PubMed Google Scholar Berenson JR, Matous J, ...